Portfolio Manager Factsheet
Shares in medical device maker Edwards Lifesciences were higher after the company posted strong first quarter earnings driven by a reacceleration in the U.S. transcatheter heart valve market. Incyte was lower after the U.S. Food and Drug Administration unexpectedly denied the approval for the company’s novel, oral therapy for the treatment of rheumatoid arthritis.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.